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Abstract Duchenne muscular dystrophy is caused by dystro-
phin de¢ciency, which can be prevented in the mdx mouse model
by over-expression of an autosomal homologue, utrophin. Utro-
phin has two characterised full-length promoters, A and B. No
data are available on the transcriptional regulation of B utro-
phin, which has been recently localised to the endothelium. Sim-
ilar to characterised endothelial promoters, Ets and Ap-1 indi-
vidually trans-activate the human B core promoter. Synergistic
activation by GATA-2 and c-jun to the order of 20-fold was
observed.
( 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Duchenne muscular dystrophy (DMD) is an X-linked
muscle wasting disease caused by the absence of a cytoskeletal
protein, dystrophin, from the cytoplasmic surface of the sar-
colemma [1]. Treatment is palliative; patients die from cardiac
or respiratory complications in their late teens or early twen-
ties. Utrophin is the autosomal homologue of dystrophin [2]
and binds similar protein complexes in muscle [3]. Therefore,
utrophin up-regulation has an inherent attraction for a ther-
apeutic strategy, as di⁄culties with immune responses associ-
ated with the introduction of dystrophin and gene delivery to
muscle may be circumvented.
Two independently regulated promoters, A [4] and B [5],
control expression of the utrophin transcript. Each promoter
gives rise to a transcript with unique 5P exons which splice
into a common utrophin mRNA at exon 3 [4,5]. Promoter A
lies within a CpG island at the 5P end of the gene [4] ; pro-
moter B is located within the large second intron of the hu-
man and mouse utrophin genes, approximately 52 and 50 kb
3P to exon 2 respectively [5]. The utrophin B transcript en-
codes a unique 31 amino acid ¢rst exon (1B), with human and
mouse sequences showing 82% nucleotide and 77% transla-
tional identity.
In a recent study, the murine utrophin B protein was local-
ised to vascular endothelia using an isoform-speci¢c antibody
[6], however, no data exist on transcriptional processes that
regulate the B transcript. This study describes the delineation
of factors from the activator protein-1 (Ap-1), Ets and GATA
families that synergistically trans-activate the human utrophin
B minimal promoter, and suggests a mechanism for endothe-
lial-speci¢c expression.
2. Materials and methods
2.1. Bioinformatics
Sequence data were assembled and analysed using the GCG Wis-
consin package; transcription factor consensus sequences and data-
bases were accessed using the TRANSFAC (http://transfac.gbf.de/
TRANSFAC/) website [7].
2.2. Electrophoretic mobility shift assay (EMSA)
Synthetic oligonucleotides (Genosys) of cognate transcription factor
binding sites were diluted to 1 Wg/Wl, with complementary primers
annealed in 1UPNK bu¡er (NEB) by heating for 5 min at 85‡c,
and cooling to room temperature overnight. EMSA analysis was per-
formed using the Gel Shift Assay System (Promega) with human
recombinant Ap-1 (c-jun; 2 Wl) and IN157 nuclear extracts, prepared
as previously described [8]. Following electrophoresis (200 V for 90
min), gels were dried and exposed for 30 min at room temperature.
2.3. Construction of utrophin luciferase vectors
Mutant sequences (changes underlined): utroB-ap1 (ctgactaaaCcg-
gacgaaa) and utroB-ets (taacttcctctCtaactgaatct) were introduced
into the de¢ned human core 300 bp promoter fragment (region
1180^1503; previously named v5PPvuII-1199 [5]) in pBluescript
KSþ=3 (Stratagene) using polymerase chain reaction mutagenesis
(Fig. 1). Conditions were 95‡c for 30 s, 12 cycles of 95‡c for 30 s,
50‡c for 1 min and 58‡c for 2 min per kb ampli¢ed. Positive clones
were identi¢ed by the abolition of restriction sites (with BstYI and
HinfI, respectively), sequenced, excised by restriction digestion (KpnI/
SacI) and directionally cloned into pGL3 Basic (Promega). Large-
scale endotoxin free plasmid preparations were puri¢ed using a com-
mercially available kit (Qiagen).
2.4. Tissue culture and transfection
Mammalian cell lines were maintained and transfected as previously
described [8]. For co-transfection of GATA, Ap-1 and Ets expression
vectors, 0.1^0.2 Wg each of vector(s) and test plasmid was used. A
stock solution (0.5 mg/ml) of 12-O-tetradecanoylphorbol-13-acetate
(TPA) was diluted in Dulbecco’s modi¢ed Eagle’s medium, and added
24 h post-transfection of reporter plasmids. Cells were allowed to
express the fusion genes for 12^24 h, and were harvested by scraping
into 1Ulysis bu¡er (Promega) after two washes in room temperature
phosphate-bu¡ered saline. Samples were freeze-thawed on dry ice,
vortexed brie£y and centrifuged (13 000 rpm for 30 s), with the super-
natant assayed directly.
2.5. Luciferase reporter gene assays
Cell extracts were assayed for luciferase activity using a commercial
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reagent (Promega). Light output was read using a Turner-TD20e lu-
minometer (delay 5 s, integrate 10 s). Assays were performed in trip-
licate from three separate cultures of transfected cells. The transfec-
tion/assay process was repeated in triplicate for all promoter studies.
3. Results
Characterised factor binding sites in a large number of
characterised core promoter regions that contribute to endo-
thelial-speci¢c expression include interactions between Sp1,
Ap-1 and the GATA and Ets transcription factor families
[9^12]. Cognate binding sites (Ap-1, Ets and Sp1) were eluci-
dated during the delineation of the minimal B promoter ele-
ment ([5], illustrated in Fig. 1), and were selected for study.
3.1. EMSA and in vitro studies of promoter activity
Functional relevance of the cognate Ap-1 site was deter-
mined using EMSA studies, where formation of endogenous
IN157 and recombinant human Ap-1 binding could both be
speci¢cally removed using an unlabelled Ap-1 consensus oli-
gonucleotide. Binding of recombinant human Ap-1 was also
disrupted by cognate site mutagenesis (Fig. 2). EMSA analysis
discounted Sp1 binding to a cognate site (1345^55; Fig. 1)
within the core promoter (data not shown).
Target nucleotides for mutagenesis of cognate binding sites
in the utrophin B core promoter were sourced using a combi-
nation of commercial mutant oligonucleotide sequences and
previous functional promoter studies of the endogenous bind-
ing a⁄nity of Ap-1 and Ets. Promoter mutants were direc-
tionally cloned into a luciferase reporter vector and function-
ally assayed by measuring their ability to drive reporter gene
expression in HeLa (cervical epithelial), IN157 (rhabdomyo-
sarcoma) and Bend3 (murine brain primary endothelial) cul-
tured cell lines in comparison to the wild-type promoter re-
gion (Fig. 3). Mutagenesis of the Ap-1 site resulted in a
decrease in promoter activity in all cell lines studied, although
the e¡ect varied from a moderate 33% decrease in HeLa
( S 3.9) to 82% (S 4.3) and 88% (S 1.1) in IN157 and Bend3
cells respectively. Removal of the cognate Ets motif exhibited
similar decreases in IN157 and Bend3 cells (87%S2.0 and
82%S8.8 respectively), with a slight increase in activity in
HeLa cells (117%S15.8). These results indicate that core pro-
moter binds members of the Ap-1 and Ets factor families
through their cognate sequences, and that these sites are nec-
essary for optimal transcription in IN157 and Bend3 cell lines.
3.2. Phorbol ester and Ap-1 trans-activation studies
As the binding of Ap-1 and Ets factors was implicated in
optimal transcriptional activity of B-utrophin, the ability of
core promoter to respond to stimulation with TPA was
studied. TPA has the ability to trans-activate a number of
characterised endothelial promoters, such as vascular endo-
thelial growth factor [13], and human intracellular adhesion
molecule-1 (ICAM-1), which results from potent up-regula-
tion of c-jun and c-fos expression via the mitogen-activated
protein kinase pathway [14]. The activation pathway of pro-
tein kinase C by TPA is reported to act on the transcriptional
level through the dephosphorylation of the C-terminal region
of c-jun and c-fos, leading to enhanced DNA binding [15,16].
Incubation with 50 and 500 ng/ml TPA caused increases in
core promoter activity in all cell lines studied. For example,
respective fold increases of 1.87 ( S 0.2) to 2.15 ( S 0.1) of core
Fig. 1. Human and mouse alignment of the utrophin B core promoter. Sequence conservation of the human (top: GenBank accession number
AJ250044) and mouse (bottom: accession number AJ250045) utrophin B region. The translated exon and conserved splice site is shown; trian-
gles de¢ne the minimal promoter element, incorporating the single transcription start site (Inr) [5]. Transcription factor binding regions of inter-
est are indicated (factor name above), Ap-1 and Ets cognate motifs (black); cognate region that did not bind Sp1 (grey); other predicted bind-
ing regions (light grey).
FEBS 27061 28-2-03
K.J. Perkins, K.E. Davies/FEBS Letters 538 (2003) 168^172 169
promoter activity were observed in the Bend3 cell line, which
was hampered by mutagenesis of the Ap-1 site, which showed
a 1.3 ( S 0.1) fold increase with 50 ng/ml TPA (Fig. 4A).
A more direct approach using c-jun and c-fos over-expres-
sion in HeLa and COS-7 cell lines was used to evaluate this
response. Dosage-dependent increases in transcriptional activ-
ity were observed with c-jun (with fold increases of 5.1 S 1.3
for 100 ng, and 9.5S 1.4 for 200 ng c-jun in HeLa cells) (Fig.
4B). Similar, albeit lower patterns of trans-activation were
observed in COS-7 cells where the highest level of activation
of 3.5-fold ( S 0.4) was observed with the co-transfection of
200 ng c-jun. Over-expression of c-fos had a positive e¡ect on
utrophin B, possibly as a consequence of complex formation
with endogenous c-jun, as members of the Fos family cannot
make stable homodimers and therefore cannot act as tran-
scriptional activators by themselves [17]. This strongly sug-
gests that the human utrophin B promoter functionally binds
members of the Ap-1 family of transcription factors, and that
c-jun homodimers are more potent in transcriptional activa-
tion of the core element than heterodimers of c-fos/jun.
3.3. Utrophin B is trans-activated by Ets family members
Ets factors often function co-operatively with other nuclear
factors, in particular Ap-1 [18]. Ets-1 and Ets-2 are expressed
in endothelial cells and speci¢cally trans-activate a large num-
ber of genes through interaction with c-jun/fos [19,20] and Sp1
[21]. PU.1 interacts via its Ets domain with the basic domainFig. 2. Ap-1 binds to the utrophin B core promoter. 20 Wg of
IN157 nuclear extract was incubated with a labelled 22-mer oligonu-
cleotide probe spanning the cognate Ap-1 site in the B promoter,
and unlabelled competitor probes as indicated by plus (+) symbols.
Two complexes were formed: Ap-1-speci¢c (grey arrow) and a non-
speci¢c binding complex (white arrow). The speci¢c complex was
competed with Ap-1 competitor only (lane 3). For recombinant pro-
tein EMSA, 2 Wg Ap-1 was added to the labelled B probe and an
Ap-1 consensus oligonucleotide probe, indicated by plus (+) sym-
bols. A speci¢c complex (grey arrow) was competed by the addition
of cold Ap-1 consensus oligonucleotide, or cognate site mutagenesis.
Black arrows represent free radiolabelled probe. Legend: IN157 ext,
IN157 nuclear extract; rh-AP1, recombinant human Ap-1 (c-jun);
c.comp, cold consensus oligonucleotide; AP1 comp, cold consensus
Ap-1 oligonucleotide; c, consensus probe; n, normal Ap-1 B pro-
moter probe; m, Ap-1 mutant B promoter probe.
Fig. 3. In vitro activity of the core B promoter is a¡ected by muta-
genesis of Ap-1 and Ets sites. Activity of the 300 bp core promoter
mutant constructs as compared to the wild-type construct. Abbrevi-
ations: 0.3B, wild-type core promoter region; others refer to the site
mutated in the reporter construct. Cell lines used as indicated; wild-
type promoter activity is represented by white columns (0.3B), with
the mutants represented as a percentage of activity.
Fig. 4. Phorbol ester and Ap-1 stimulate the utrophin B promoter.
A: The core promoter exhibits a dosage response to the addition of
the phorbol ester TPA in HeLa, Bend3 and IN157 cells. Activities
of the core (0.3pB) and the Ap-1 mutant (Ap-1) promoter regions
are indicated, with addition of 50 ng and 500 ng/ml TPA repre-
sented by ‘50’ and ‘500’ on the respective columns. Activity is ex-
pressed as a ratio of luciferase activity relative to the Renilla trans-
fection control. B: The utrophin B core promoter element exhibits a
dosage response to raised levels of c-jun and c-fos in HeLa and
COS-7 cell lines. Cells were transfected with 100 ng of the B pro-
moter region, and 100^200 ng of c-jun and/or c-fos as indicated by
plus (+) symbols in the ¢gure legend. Activity is expressed as the
fold di¡erence over the normalised B promoter value.
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of c-jun [22]. The B core promoter reporter construct was co-
transfected in HeLa cells with Ets-1, Ets-2 and PU.1 expres-
sion vectors. Ets-1 exhibited the highest fold increase
(6.3 S 0.6), although PU.1 (4.3 S 1.02) and Ets-2 (3.5 S 0.41)
also showed measurable e¡ects on promoter activity. Trans-
activation levels were hampered by the Ets mutant, of which
the highest fold increase over wild-type promoter activity was
observed with Ets-2 (2.18S 0.5). Co-transfection with c-jun or
c-fos led to a further increase in core promoter activity (Fig.
5), with the highest level of trans-activation observed with
PU.1 and c-jun (16.7 S 0.59 fold). Both c-jun and c-fos re-
sulted in a 23-fold increase in promoter activity (22.96 S
0.5), with similar levels observed for PU.1 (21S 0.65). Levels
of Ets-2-mediated trans-activation were comparatively lower
(7S 0.6).
A limited degree of synergistic co-operation between Ap-1
and Ets factor families was noted, i.e. combined trans-activa-
tion of c-jun and PU.1 resulted in an almost two-fold increase
over the expected value of the two factors individually (from
an expected value of V9.36- to almost 17-fold). Conversely,
most Ets/Ap-1 combinations showed similar trans-activation
values whether individually or co-transfected. For example,
the sum of individual values obtained with transfection of
c-jun (V5.1) and Ets-2 (V3.7) is similar to the co-transfected
value of 9.5. Therefore, the degree of synergism (if any) be-
tween Ets and Ap-1 families to transcriptionally regulate the
B core promoter appears complex and is likely to be reliant on
speci¢c combinations and/or individual factor availability. As
exhibited by c-jun/fos over-expression (Section 3.2), co-trans-
fection with c-jun appeared to be more potent in conferring a
positive response from the core promoter, with reporter tran-
scription levels generally two-fold higher than observed for
c-fos.
3.4. GATA and Ap-1 factors synergistically activate utrophin B
GATA factors play a critical role in mediating transcrip-
tional regulation of several endothelial-speci¢c genes. This
phenomenon is particular to GATA-2, which is abundantly
expressed in endothelia and is critical for transcriptional reg-
ulation of ET-1 (endothelin-1 (ET-1), a potent vasoconstrictor
and smooth muscle mitogen expressed in endothelial cells of
the vascular wall) [23], von Willebrand factor [24], ICAM-2
and P-selectin (both adhesion receptors constitutively ex-
pressed in megakaryocytes and endothelial cells [9,25,26].
GATA factor transfection resulted in low levels of tran-
scriptional activation from the utrophin B minimal element,
i.e. 1.6 ( S 0.1) and 1.3 ( S 0.1) fold for GATA-2 and -3. How-
ever, co-transfection with c-jun (individually conferring a ¢ve-
to seven-fold increase) showed a signi¢cant increase in utro-
phin B reporter activity (Fig. 5). Augmented trans-activation
potential was most apparent with GATA-2 (19.56S 0.86),
although GATA-1 (8.0 S 1.8) and -3 (13.5 S 2.4) were also
responsive. Functional synergism between GATA and Ap-1
factor families was enhanced in comparison to Ap-1/Ets, and
de¢nes an additional/related regulatory mechanism residing
within the utrophin B core promoter region.
4. Discussion
The utrophin B isoform has been recently localised to the
endothelium [6]. This paper describes the analysis of signalling
pathways and transcriptional mechanisms that may confer
endothelial-speci¢c transcription.
In addition to the functional analysis of a cognate Ap-1 site
present within the minimal promoter region, mutagenesis of a
cognate Ets site resulted in a severe attenuation of utrophin B
reporter activity in gliomal IN157 and endothelial Bend3 cell
lines. Three Ets factor family members are able to trans-acti-
vate the utrophin B promoter (of which Ets-1 and Ets-2 are
expressed in endothelia). This suggests that B utrophin is sub-
ject to regulatory mechanisms observed for vascular bed-spe-
ci¢c genes, such as platelet endothelial cell adhesion molecule-
1 (PCAM-1) [27] and endothelial cell-speci¢c molecule-1 [28],
in which functional synergism between the Ets, Ap-1 or Sp1
factor families exists. Observed trans-activation levels are
comparable to the von Willebrand factor core promoter (re-
Fig. 5. Utrophin B is trans-activated by GATA, Ets and Ap-1 factors. The human utrophin B core promoter is activated by Ets factors and
the synergistic co-operation of GATA and Ap-1. HeLa cells were transfected with 100 ng of the B promoter core construct, and 100 ng of Ets
or GATA factors (indicated above), with 100 ng c-jun and/or c-fos indicated by plus (+) symbols in the ¢gure legend and light grey (c-jun),
dark grey (c-fos) and black (c-jun and c-fos) columns. Asterisks indicate values obtained for the Ets mutant. Activity is expressed as the fold
di¡erence over the normalised wild-type B promoter value.
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stricted to endothelial cells and megakaryocytes) in which
Ets-1, Ets-2 and Erg can trans-activate transcription approx-
imately four-fold [29,30]. Co-transfection of Ets and Ap-1
factors resulted in a limited degree of co-operativity to up-
regulate the B core element and suggested that alternative
mechanisms may exist.
GATA factors (most notably GATA-2) showed co-opera-
tivity with Ap-1 to increase transcription in a greater than
additive manner in a non-endothelial cell line; illustrated for
other endothelial-speci¢c promoters [31,32], such as the hu-
man ET-1 core promoter, where a GATA/Ap-1 site is capable
of conferring on a heterologous promoter enhanced expres-
sion in endothelial cells [23]. Signi¢cant increases were only
observed with co-transfection with members of the Ap-1 fam-
ily and GATA-2 with c-jun/fos vastly increases transcription
[32]. GATA trans-activation levels observed for utrophin B
with or without the presence of Ap-1 are similar to those
observed for the ET-1 core promoter by Kawana et al. [32]
and strongly suggest that mechanisms governing the spatial
expression of utrophin B may be compatible, in part, to those
elucidated for ET-1.
The cis-acting GATA regulatory sequence responsible was
not identi¢ed, although a putative site was identi¢ed at the
most 5P end of the core promoter region (Fig. 1), adjacent to
an additional Ets site. Mutagenesis studies were not per-
formed as a GATA binding motif may not be required, as
GATA-2 can potentiate the action of Ap-1 with a GATA site
deletion, and vice versa [32]. As GATA-2 and Jun/Fos family
members are widely expressed, their sole action cannot be
responsible for such cell-restricted behaviour, and may allow
recruitment of additional proteins, such as the Ets and Sp
transcription factor families. Sp1 co-operability with Ets and
GATA factors is critical for core promoter transcription of
several endothelial genes, such as Tie-2 [10], Flt-1 [33], ICAM-
1 [25], PCAM-1 [27,34] and the endothelial nitric oxide syn-
thase enhancer [35]. Although Sp1 did not bind a designated
region in the B core promoter element, alternative sites may
exist or may not be required, as this factor can interact di-
rectly with bound Ets-1 [36].
Selective formation of multiple protein complexes involving
members of the Ets, GATA, Ap-1 and possibly Sp factor
families may therefore be important for both spatial restric-
tion and enhanced function of the utrophin B promoter in
endothelium. This study therefore provides an insight into
mechanisms directing cellular distribution of utrophin B,
which is necessary for de¢ning the potential of using alterna-
tive isoforms to utrophin A in an up-regulation-based therapy
for DMD.
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